BioSyntech announces five poster presentations at 54th Annual Meeting of the Orthopaedic Research Society



    LAVAL, QC, March 4 /CNW/ - BioSyntech, Inc. ("BioSyntech" or "the
Company") (TSX: BSY), a biotechnology company developing biotherapeutic
thermogels for regenerative medicine, today announced that five abstracts have
been selected for presentation as posters at the 54th Annual Meeting of the
Orthopaedic Research Society ("ORS") held from March 2-5, 2008 in San
Francisco, California. The poster presentations will showcase research
performed in the area of surgical techniques and solutions for meniscus and
cartilage repair. BioSyntech's product portfolio includes several orthopedic
products in development, including BST-CarGel(R) for cartilage repair and
Arthro-BST(TM), an arthroscopic instrument for the assessment of articular
cartilage.
    "The acceptance of these abstracts in this meeting is an important
accomplishment for our Company, demonstrating the high level of interest in
our orthopedic products and the quality of our research," said Claude LeDuc,
President and CEO. "The abstracts emerged from our longstanding partnership
with the Biomaterials and Cartilage Laboratory at the Ecole Polytechnique de
Montreal, led by Professor Michael D. Buschmann. We look forward to leveraging
joint research efforts and showcasing both Arthro-BST(TM) and BST-CarGel(R),
our minimally invasive solutions for the measurement and repair of damaged
tissue."

    The following five abstracts will be presented:

    Abstract Number 0483:
    "Chondrocyte aggregation in suspension culture is mediated by integrins
    and collagen"
    Gigout, Anne; Jolicoeur, Mario; Buschmann, Michael

    Abstract Number 0538:
    "A comparative study of microfracture and drilling surgical techniques
    for cartilage repair"
    Chen, Hongmei; Sun, Jun; Chevrier, Anik; Lascau-Coman, Viorica; Ouyang,
    Wei; Hoemann, Caroline D.; McKee, Marc D.; Shive, Matthew S.; Buschmann,
    Michael D.

    Abstract Number 0629:
    "Non-Homogeneous Electromechanical Properties of Articular Cartilage
    Predict an Electrical Potential of Positive Polarity Outside Cartilage"
    Garon, Martin; Buschmann, Michael D.

    Abstract Number 0723:
    "Evaluation of a Medical Device for Assessment of Cartilage Degeneration
    After Impact Injury"
    Hurtig, Mark ; Eric, Quenneville; Martin, Garon; Michael, Buschmann;
    Legare, Anne

    Abstract Number 1287:
    "Interspecies comparison of meniscus structure in human, sheep and
    rabbit"
    Chevrier, Anik .; Sun, Jun; Hurtig, Mark B.; Hoemann, Caroline D.;
    Buschmann, Michael D.

    Additional information on these abstracts can be found at the Orthopaedic
 Research Society's website at www.ors.org/web/index.asp

    About BioSyntech

    BioSyntech is a medical device company specialized in the development,
manufacturing and commercialization of advanced biotherapeutic thermogels for
regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's
platform technology is a family of hydrogels called BST-Gel(R), liquid at low
temperature and solid at human body temperature. These gels can be injected or
applied to a specific local site and offer beneficial properties for the local
repair of damaged tissue such as cartilage, bone and chronic wounds and
provide the benefit of avoiding invasive surgery. The Company's two lead,
late-stage products, BST-CarGel(R) and BST-DermOn(TM), are currently
undergoing Canadian and European pivotal trials. For additional information,
visit www.biosyntech.com.

    Forward-Looking Statements

    This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the adequacy, timing, and results of our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, the success of research and
development programs, reliance on subcontractors and key personnel, and other
risks and uncertainties detailed from time-to-time in our filings with the
Canadian securities commissions.
    Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information about (i) the material factors that could cause actual results to
differ materially from the conclusion, forecast or projection in the
forward-looking information, and (ii) the material factors or assumptions that
were applied in drawing a conclusion or making a forecast or projection as
reflected in the forward-looking information, is contained in the Company's
annual report and other documents filed from time to time with the Canadian
securities commissions which are available at www.sedar.com. These statements
speak only as of the date they are made, and we assume no obligation to revise
such statements as a result of any event, circumstance or otherwise, except in
accordance with law.

    %SEDAR: 00020217EF




For further information:

For further information: BioSyntech, Inc., Yvonne Kramer Ph.D., Sr.
Director Corporate & Business Development, Tel: (450) 686-2437, ext. 315,
Yvonne.Kramer@biosyntech.com; The Equicom Group, Arianna Vanin, Investor
Relations, Tel: (514) 844 -4680, avanin@equicomgroup.com

Organization Profile

BIOSYNTECH, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890